Mizuho's Jared Holz talks Novo Nordisk falling on Alzheimer's trial

Transcript

expectations for its own drug for stroke prevention and Merck up nearly 3%. Upgraded to outperform at Wells Fargo on optimism around its pipeline build. For more on the moves, Mizuho healthcare strategist Jared Holmes joins us here on set. Jared, great to have you with us. It felt like the bar was sort of low when it comes to Novo and the Alzheimer... Read More